Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Core Insights - Candel Therapeutics, Inc. (NASDAQ: CADL) has experienced significant volatility since December, with a maintained "Buy" sentiment due to positive developments in the company [1] Company Overview - Candel Therapeutics is focused on the biotech sector, particularly in the analysis of clinical trials and the science behind its business operations [1] Investment Sentiment - The article emphasizes the importance of due diligence in biotech investments, highlighting the potential pitfalls that investors may encounter [1]